Top Page
EMvision Medical Devices Ltd.
(Sydney:EMV)
EMvision Medical Devices Ltd. (EMV) vs. iShares MSCI Australia ETF (EWA)
EMvision Medical Devices Ltd. Business Overview & Revenue Model
EMvision Medical Devices Ltd. Financial Statement Overview
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 11.22M | 6.97M | 4.36M | 1.70M | 1.55M |
| Gross Profit | 11.22M | 6.63M | 4.12M | 1.58M | 1.55M |
| EBITDA | -2.09M | -3.49M | -7.84M | -9.56M | 0.00 |
| Net Income | -2.73M | -3.87M | -6.11M | -8.40M | -3.48M |
Balance Sheet | |||||
| Total Assets | 23.97M | 11.52M | 8.51M | 10.77M | 6.01M |
| Cash, Cash Equivalents and Short-Term Investments | 18.67M | 9.97M | 6.80M | 9.69M | 5.41M |
| Total Debt | 2.90M | 3.04M | 737.86K | 213.17K | 0.00 |
| Total Liabilities | 5.46M | 6.40M | 1.43M | 720.01K | 489.73K |
| Stockholders Equity | 18.52M | 5.12M | 7.08M | 10.05M | 5.52M |
Cash Flow | |||||
| Free Cash Flow | -6.29M | 646.86K | -3.97M | -4.62M | -3.26M |
| Operating Cash Flow | -5.99M | 834.15K | -3.78M | -4.49M | -3.26M |
| Investing Cash Flow | -302.41K | -187.29K | -191.12K | -127.25K | 0.00 |
| Financing Cash Flow | 15.00M | 2.52M | 1.08M | 8.90M | 4.28M |
EMvision Medical Devices Ltd. Technical Analysis
EMvision Medical Devices Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | CHF26.60B | 17.29 | 9.71% | 2.35% | 21.08% | 2.84% | |
63 Neutral | AU$215.65M | ― | -4.06% | ― | 20.36% | 64.81% | |
58 Neutral | AU$56.70M | ― | -8.08% | ― | -5.62% | -225.71% | |
52 Neutral | AU$246.74M | ― | -52.37% | ― | 471.29% | -4.58% | |
46 Neutral | AU$145.81M | ― | -58.61% | ― | ― | -74.88% | |
| ― | $58.63M | ― | -51.08% | ― | ― | ― | |
44 Neutral | AU$106.69M | ― | -35.20% | ― | 4.68% | -155.42% |
EMvision Medical Devices Ltd. Corporate Events
EMVision Medical Devices Ltd. has reported significant progress in its clinical, regulatory, and commercialization efforts for its emu™ and First Responder devices. The company is advancing its emu™ brain scanner through a pivotal trial aimed at securing FDA De Novo clearance, with multiple high-volume sites actively recruiting participants. Additionally, the First Responder device has successfully undergone aeromedical testing and is set for further pre-hospital studies. EMVision has also been awarded a $5 million grant to accelerate the commercialization of the First Responder device and has expanded its production capabilities. These developments position EMVision strongly in the neurodiagnostic industry, with potential implications for improved patient outcomes and expanded market opportunities.
EMVision Medical Devices Ltd has achieved a significant milestone in its First Responder portable brain scanner program, receiving ethics approval for two studies that will advance the device towards commercialization. These studies, involving collaborations with the Royal Flying Doctor Service and Melbourne Mobile Stroke Unit, aim to demonstrate the device’s integration into emergency workflows and its potential impact on patient care. The company has also received a $400,000 milestone payment from the Australian Stroke Alliance, highlighting the progress in their development efforts and the potential transformation in pre-hospital neurodiagnostic capabilities.
EMVision Medical Devices Ltd has been awarded a $5 million non-dilutive grant from the Australian Government’s Industry Growth Program to support the global commercialization of its First Responder portable brain scanner. This funding is a significant endorsement of the device’s potential to revolutionize pre-hospital care for stroke and traumatic brain injuries by enabling quicker diagnosis and treatment decisions, which can ultimately save lives and reduce disabilities. The grant highlights the advanced development stage and unique value proposition of EMVision’s technology, as recognized by healthcare professionals both domestically and internationally.
EMVision Medical Devices Limited has appointed Carmel Monaghan as an Independent Non-Executive Director. Ms. Monaghan, currently the CEO of Ramsay Healthcare Australia, brings extensive experience in healthcare leadership, corporate strategy, and marketing. Her appointment comes as EMVision is undergoing pivotal trials for regulatory clearance, positioning the company for growth and commercialization of its neurodiagnostic products. This strategic move is expected to enhance EMVision’s capabilities in addressing unmet patient needs, particularly in the areas of stroke and traumatic brain injury, which are significant global health challenges.
EMVision Medical Devices Ltd announced the appointment of Carmel Monaghan as a director effective June 5, 2025. The notice indicates that Monaghan currently holds no securities in the company, suggesting a focus on governance and strategic oversight rather than financial interest. This appointment may influence the company’s strategic direction and strengthen its leadership team, potentially impacting its market positioning and stakeholder relations.
EMVision Medical Devices Ltd has announced the activation of two additional sites for its pivotal trial of the emu™ bedside brain scanner, with Mount Sinai in New York and Liverpool Hospital in Sydney joining the study. These activations bring the total to five sites, with a sixth to follow, as part of efforts to validate the device’s diagnostic performance for FDA De Novo clearance. The trial aims to demonstrate the scanner’s potential to improve stroke diagnosis and treatment outcomes by enabling rapid differentiation of stroke types at the point-of-care.
EMVision Medical Devices Ltd has announced significant improvements in its AI-powered ‘ischemia or not’ diagnostic algorithm, achieving 95% sensitivity and 80% specificity in recent tests. These enhancements are part of the company’s ongoing innovation efforts and are expected to support the validation and potential FDA clearance of their emu™ brain scanner device, which could have substantial implications for stroke diagnosis and treatment.